The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The present research aimed to analyze the impacts of magnesium and zinc supplements on glycemic control, serum lipids, and biomarkers of oxidative stress and inflammation in patients suffering from coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM).

Current Controlled Trials http://www.irct.ir: IRCT20130211012438N31 at 11 May 2019 of registration.

Who Took Part

The study group was 60 subjects.

According to the research design, a randomized, double-blind, placebo-controlled trial has been implemented on 60 subjects suffering from CHD and T2DM.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The subjects were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the subjects and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some subjects received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

The subject headings attached to it are Antioxidants, Blood Glucose, C-Reactive Protein, Cholesterol, HDL, Coronary Disease, Diabetes Mellitus, Type 2 and Dietary Supplements.

Author keywords: Coronary heart disease, Magnesium, Metabolic status, Type 2 diabetes mellitus and Zinc.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 60 subjects.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Lipids in health and disease), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.